New stem cell method aims to cut transplant risks
NCT ID NCT01174108
First seen Jun 25, 2026 · Last updated Sep 17, 2026 · Updated 8 times
Summary
This study tests a new way to do stem cell transplants for people with severe aplastic anemia or other bone marrow failure diseases. Doctors give a smaller number of donor white blood cells along with the stem cells to try to reduce serious side effects. Up to 120 patients aged 4 to 80 will take part, and they will be followed for up to 3 years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Donor stem cells and white blood cells
- What this could lead to
- If successful, this approach could make stem cell transplants safer and more effective for people with severe blood diseases.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. There are still risks of serious side effects like graft-versus-host disease or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2010
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Recipient: * Patients diagnosed with one of the following hematologic diseases which are associated with reasonable longevity, shown to be curable by allogeneic BMT but where concern for a high procedural mortality with conventional BMT may delay or prevent such treatment: * 1\) Paroxysmal nocturnal hemoglobinuria (PNH) associated with life-threatening thrombosis, and/or cytopenia, and/or transfusion dependence and/or recurrent and debilitating hemolytic crisis * 2\) Severe aplastic anemia (SAA) or pure red cell aplasia (PRCA \[acquired or congenital\]) with bone marrow cellularity \<30% (excluding lymphocytes) associated with RBC or platelet transfusion dependence and/or neutropenia (absolute neutrophil count \<=1000 cells/uL or for patients receiving granulocyte transfusions, absolute neutrophil count \<=1000 cells/ uL before beginning granulocyte transfusions). in newly diagnosed patients and/or in patients who have failed immunosuppressive therapy. * 3\) Refractory anemia (RA) or RARS MDS patients who have associated transfusion dependence and/or neutropenia. * Ages 4 to 80 (both inclusive), and weight \>15 kg * Availability of HLA identical or single HLA locus mismatched family donor or 10/10 matched unrelated donor at the allelic level (HLA alleles A, B, C, DR, and DQ). * 9/10 donors where all the HLA sequences have the same antigen/peptide binding domains in key exons to the patient. This can result in identical protein sequences between patient and donor. Allele mismatches in p and g groups can be considered acceptable due to the exact matching which exists in the binding domains. * Telomere Length Testing * Germline/Inherited gene panel in patients where a suspicion for a familial bone marrow failure syndrome (BMFS) exist, hTERC and hTERT, GATA2 mutation testing will be performed on protocol 04-H-0012 or performed elsewhere prior to enrolling on 04-H-0012. EXCLUSION CRITERIA: \- Recipient: any of the following * Major anticipated illness or organ failure incompatible with survival from PBSC transplant * Diffusion capacity of carbon monoxide (DLCO) \<40% predicted (patients under the age of 10 may be excluded from this criterion if they have difficulty performing the test correctly and thus are unable to have their DLCO assessed) using DL Adj and DL/VA/Adj. * Left ventricular ejection fraction \<40% (evaluated by ECHO) * Serum creatinine greater than 2.5mg/dl or creatinine clearance less than 50 ml/min by 24 hr urine collection * Serum bilirubin greater than 4 mg/dl, transaminases greater than 5 times the upper limit of normal * Pregnant or lactating * Fanconi s anemia (test to be performed at a CLIA-certified laboratory) * ECOG performance status of 3 or more (See NIH Bone \& Marrow Transplant Consortium Supportive Care Guidelines for HSCT Recipients or Institutional Guidelines for bone and marrow transplants) * Other malignant diseases liable to relapse or progress within 5 years, with the exception of a separate hematologic malignancy where allogeneic stem cell transplant has been shown to be potentially curative. * Presence of an active infection not adequately responding to appropriate therapy. * Inability to comprehend the investigational nature of the study and provide informed consent. The procedure will be explained to subjects age 8 -17 years with formal consent being obtained from parents or legal guardian. INCLUSION CRITERIA: -Related Donor: * Related donor deemed suitable and eligible, and willing to donate, per clinical evaluations who are additionally willing to donate blood samples for research. Related donors will be evaluated in accordance with existing Standard Policies and Procedures for determination of eligibility and suitability for clinical donation. Note that participation in this study is offered to all related donors, but study participation is not required for a donor to make a stem cell donation, so it is possible that not all related donors will enroll onto this study * Age greater than or equal to 4 and less than or equal to 80 years old EXCLUSION CRITERIA: -Related Donor: None INCLUSION CRITERIA \& EXCLUSION CRITERIA: Unrelated Donor \- The NMDP unrelated donor inclusion criteria will be used as outlined in document (http://bethematch.org/WorkArea/DownloadAsset.aspx?id=1960). Donor eligibility will be completed per NMDP standards and in accordance with most recent and stringent FDA guidelines.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS (myelodysplastic syndrome) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
-
University of Maryland, Baltimore (UMB)
COMPLETEDBaltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden blood disorder may explain mysterious strokes in young adults
- Half-Matched stem cell transplants tested as a cure path for older aplastic anemia patients
- Can a drug duo keep High-Risk blood cancers at bay after transplant?
- Can a new pill boost the power of an existing leukemia treatment?
- A pill that could replace infusions for a rare blood disease?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?